Sector News

BioAmber announces new Chief Executive Officer

September 15, 2017
Life sciences

The Board of Directors of BioAmber Inc. is pleased to announce the appointment of Richard P. Eno as its new Chief Executive Officer, and new member of the Board, effective September 18th, 2017. The selection of Mr. Eno caps a search process facilitated by Spencer Stuart, a global executive search firm which specializes in placing senior management personnel.

Mr. Eno has over 30 years of related management experience in the energy, chemicals, biotechnology and materials industries, including over five years as President, CEO and Board member of a publicly traded industrial biotechnology company. Rick began his career in Chevron’s chemical operations with roles of increasing responsibility in engineering, manufacturing and construction operations. He then entered management consulting where he specialized in addressing critical strategic and operational issues facing company leadership in the chemical and energy industries. In 2008, he took up leadership of Metabolix, an industrial biotechnology company commercializing a range of unique bio-based, biodegradable polymers. Most recently, Rick has been a senior partner at a global management consultancy, Roland Berger, focused on the chemicals industry.

“The Board is pleased to have found an individual with an ideal industry background as well as public company experience to assume leadership of BioAmber. Rick is uniquely qualified to lead BioAmber successfully into the future,” said Ray Land, BioAmber’s Chairman of the Board.

“I am enthused to joining the BioAmber team,” added Rick Eno. “The company’s bio-succinic technology operates superbly at scale, there is a rich pipeline of attractive customer opportunities, and a world class team in place. I look forward to leading the growth of this highly innovative company.”

Rick has a B.S. in Chemical Engineering from Cornell University, a Masters in Business Administration from the University of Houston and is a Chartered Financial Analyst (CFA). He currently serves on the President’s Council for Ceres, a non-profit promoting a sustainable future; the alumni advisory Board for Cornell University’s School of Chemical and Biomolecular Engineering; and on the alumni advisory board for Cornell’s Atkinson’s Center for a Sustainable Future.

Source: BioAmber

comments closed

Related News

June 8, 2024

Lilly CFO leaves to join Alphabet

Life sciences

Anat Ashkenazi will leave Eli Lilly’s executive suite at the end of July to become CFO and senior vice president of Google and Alphabet. Ashkenazi has been CFO at Lilly since 2021 and originally joined the company in 2001. Over her 23-year career at the Indianapolis-based drugmaker, Ashkenazi also served as controller, CFO of Lilly Research Laboratories and as the finance chief for several global divisions within the company.

June 8, 2024

Edwards Lifesciences to cell Critical Care to BD

Life sciences

Edwards Lifesciences (NYSE: EW) announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company), in an all-cash transaction valued at $4.2 billion. With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care.

June 8, 2024

Danaher names Martin Stumpe as chief data and AI officer

Life sciences

The company, which owns diagnostics and life sciences businesses including Beckman Coulter and Cepheid, said the appointment reflects its increasing investment in AI as “a driving force for innovation and productivity.” Danaher is focused on AI by also spending on its internal capabilities and partnering with academic groups.

How can we help you?

We're easy to reach